Hologic (HOLX) Q1 2026 earnings review
Buyout Pending: Mixed Results Underscore Deal Timing
Hologic reported a tepid Q1 with revenue growing just 2.5% to $1.05B and Non-GAAP EPS edging up 1% to $1.04. The impending acquisition by Blackstone and TPG likely comes at the right time: operational friction is visible. Tariffs crushed gross margins by 150 basis points, and the core Diagnostics segment contracted 1.3%. While Surgical and Skeletal provided lift, the growth quality was low, driven largely by M&A and easy comparisons. With guidance withdrawn and the merger vote set for Feb 5, 2026, operational scrutiny takes a backseat to deal closure.
🐂 Bull Case
Surgical revenue grew 8.7% (3.2% organic), driven by the integration of Gynesonics and strong performance from MyoSure and Fluent. This segment remains the most reliable growth engine outside of cyclical fluctuations.
Despite margin pressure, Operating Cash Flow jumped 21.4% YoY to $229.9M. The balance sheet is robust with $2.17B in cash and a net leverage ratio of just 0.3x, ensuring stability through the merger close.
🐻 Bear Case
Tariffs are no longer a theoretical risk—they are a bottom-line hit. Tariff expenses reached $15.3M in the quarter, driving a 150 basis point compression in Non-GAAP Gross Margin to 60.1%. Pricing power has not yet offset these costs.
The largest segment, Diagnostics, fell 1.3% YoY. Even excluding COVID noise, organic constant currency growth was effectively zero (-0.3%). Weakness in molecular diagnostics (-3.5%) offsets gains elsewhere.
⚖️ Verdict: ⚪
Neutral. The operational results are mediocre—margin compression and stagnant organic diagnostics sales are concerning. However, the pending acquisition ($79/share) renders fundamental analysis largely moot for long-term holders, effectively putting a floor under the stock.
Key Themes
Tariffs Crush Gross Margins
Tariffs hit hard in Q1. Non-GAAP Gross Margin fell 150 bps YoY to 60.1%, explicitly driven by $15.3M in increased tariff expenses. This contradicts earlier management optimism about mitigation. Without the ability to pass these costs onto customers immediately, profitability leverage is breaking down despite revenue growth.
Surgical Segment Outperformance
Surgical remains a bright spot, growing 8.7% reported and 7.5% in constant currency. While the Gynesonics acquisition provided a ~5.5% inorganic boost, organic growth of 3.2% (2.0% CC) is still positive relative to the broader portfolio. Gynesonics, MyoSure, and Fluent are performing well, validating the M&A strategy.
Molecular Diagnostics Weakness
Molecular Diagnostics, the company's profit engine, declined 3.5% reported (-4.6% constant currency). While COVID declines are known, the weakness extended beyond that. Excluding COVID, organic molecular growth was flat (0.0% CC). Lower sales of legacy STI assays dragged down performance, barely offset by BV/CV/TV growth.
Skeletal Health Bounce Back
Skeletal Health revenue surged 69% YoY to $26.7M. This is a massive acceleration but largely optical—it reflects a recovery from supply chain stops and easy comps in the prior year (where revenue was only $15.8M). It is not a sustainable long-term trend but provided a necessary boost to Q1 top-line figures.
Pending Acquisition by Blackstone/TPG
Hologic has entered a definitive agreement to be acquired. Consequently, the company withdrew all guidance and cancelled the earnings call. Shareholder vote is scheduled for February 5, 2026. This effectively freezes strategic communication and shifts investor focus entirely to deal closure probability.
Breast Health Stability
Breast Health grew 1.8%, stabilized by the Endomagnetics acquisition (Interventional Breast Solutions grew 9.6%). However, the core Breast Imaging business (mammography) remains soft, declining 0.6% YoY (-1.6% CC). The segment is treading water rather than driving growth.
Other KPIs
Accelerating. Up 21.4% YoY. Despite net income dropping on a GAAP basis due to FX, working capital improvements drove strong cash generation. This reinforces the 'cash cow' thesis attractive to private equity buyers.
Decelerating. Down 10.9% YoY. The decline was driven primarily by FX headwinds (prior year had gains) and the $15.3M tariff impact. GAAP margins contracted significantly (Net Margin 17.1% vs 19.7% prior year).
Reversing. Declined 1.3% YoY after showing growth in prior quarters. The 'post-COVID' normalization tailwind has faded, revealing sluggish core demand in legacy testing products.
Guidance
Reversing. The company suspended all financial guidance due to the pending acquisition by Blackstone and TPG. No forecasts for revenue or EPS were provided.
Key Questions
Tariff Mitigation Strategy
Tariffs impacted Gross Margin by 150bps ($15.3M) this quarter. Since you are not providing guidance, should we assume this run-rate of ~$60M annual impact is the new baseline, or are there supply chain adjustments in motion to reduce this before fiscal year-end?
Molecular Diagnostics Stagnation
Organic Molecular Diagnostics growth (ex-COVID) flatlined at 0.0% constant currency. Is this purely a function of legacy STI declines, or are you seeing competitive pressure on the Panther platform's core menu?
Surgical Organic Growth
Surgical reported 8.7% growth, but organic constant currency growth was only 2.0%. This is a deceleration from the high-single-digit trends seen in FY25. Is the MyoSure/NovaSure franchise reaching saturation in the U.S. market?
Capital Equipment Environment
Breast Imaging revenue declined 1.6% in constant currency. Are you seeing hospital capital budget tightening accelerate in the current interest rate environment, and does this risk the 'upgrade cycle' thesis for the new year?